This Biotech Services Stock Rises 43% in 6 Months: What Powered the Rally?

This biotech services stock has turned Rs 1 lakh into roughly Rs 1.43 lakh in six months. One Bengaluru-based drug research and manufacturing partner delivered a 6-month return of 43.28% as of 10 September 2026, ranking 35th in a screen of 101 large-cap and mid-cap NSE shares.

The company is Anthem Biosciences Ltd (NSE: ANTHEM), a contract research, development and manufacturing organisation (CRDMO) that works for global pharma and biotech innovators. The Anthem Biosciences share price closed at Rs 942.30 on 10 September 2026, giving it a market value of approximately Rs 53,083 crore. This biotech services stock listed in July 2025 at an IPO price of Rs 570 and now trades about 65% above that issue price.

Click Here – Get Free Investment Predictions

How Much Has This Biotech Services Stock Gained in 6 Months?

This biotech services stock has gained 43.28% in six months, placing it 35th out of 101 screened NSE stocks. The Anthem Biosciences share price ended flat on 10 September 2026, slipping just Rs 0.65 from the previous close of Rs 942.95 after moving between Rs 934 and Rs 959.20 during the session.

For this biotech services stock, the 52-week range runs from a low of Rs 579.15 to a high of Rs 977.55, so the share sits about 63% above its low and roughly 4% below its peak. Here is how the biotech services stock has performed across time frames in our screen:

Period	Return (%)	Rank (out of 101)
1 Month	6.80%	32
6 Months	43.28%	35
1 Year	25.04%	54
Since Listing (July 2025)	32.65%	Not ranked

Returns are simple price changes and are not annualised. The since-listing figure is measured from the first trading day, when shares opened at Rs 723.05 on the NSE, a premium of about 27% over the Rs 570 IPO price. Allottees who received shares in the IPO are sitting on a much larger gain of roughly 65%.

There has been no stock split or bonus issue since listing, so the 43% move in this biotech services stock is genuine price appreciation. The pattern is uneven, though. The share spent much of its first year trading below its debut level before the recent run lifted it to fresh highs.

Why Did This Biotech Services Stock Rise 43% in 6 Months?

This biotech services stock rose because a record Q4 FY26 result reset earnings expectations, marquee institutions bought a large promoter block, net cash kept piling up and management guided that customer destocking was over. A sector-wide shift of drug outsourcing work away from China added a tailwind.

1. A Record Q4 FY26 Result Reset Expectations

The biggest trigger for the biotech services stock came in May 2026. Q4 FY26 revenue rose about 26% year on year to Rs 611 crore, while net profit jumped around 130% to roughly Rs 190 crore. Company-reported EBITDA climbed 52% to Rs 318 crore, taking the EBITDA margin to 48.1%.

For the full year FY26, revenue grew about 18% to around Rs 2,280 crore on a total income basis and profit after tax rose 31% to Rs 592 crore. The CRDMO segment, which brings in about 83% of revenue, grew 31% in the March quarter alone. For a biotech services stock valued on growth, those numbers mattered.

2. Institutions Absorbed a Large Promoter Block

On 18 June 2026, a promoter sold about 1.71 crore shares, close to 3% of the company, at an average price of approximately Rs 744.80, raising around Rs 1,275 crore. Foreign funds and a long list of domestic mutual funds and insurers took up the shares.

Promoter stake sales often weigh on a stock. Here the opposite happened because the buyers were long-term institutions. DII holding rose from 7.21% in September 2025 to 13.48% by June 2026, widening the investor base of this biotech services stock and improving liquidity.

3. Management Says Destocking Is Largely Over

On the Q4 call, the management of this biotech services stock said destocking issues were largely behind the company and that it was targeting a return to its historical 20% growth path in the CRDMO business. It also added two direct relationships with large global pharma companies.

After a softer June quarter, management said it had around 60% revenue visibility for FY27 and remained confident about regaining a mid-teens growth rate as deliveries pick up in the second half.

4. A Rs 1,200 Crore Capacity Plan and a Cash-Rich Balance Sheet

The company behind this biotech services stock is building Unit 4, a greenfield project of approximately Rs 1,200 crore spread over two years. Phase 1 is targeted by March 2028 and is expected to double custom synthesis capacity while lifting fermentation capacity by about 50%, including capacity for peptides and complex molecules.

Funding is not a worry. Net cash stood at approximately Rs 1,720 crore on 30 June 2026, up from about Rs 1,375 crore at the end of FY26. Borrowings were only around Rs 54 crore in March 2026, so this biotech services stock is effectively debt free.

5. China Plus One Tailwind for Indian CRDMOs

US lawmakers have pushed to limit reliance on certain Chinese biotech suppliers, and global drug makers are diversifying their research and manufacturing partners. Indian CRDMOs are key beneficiaries, and investors have rewarded companies with a track record of complex chemistry, fermentation and biologics work. This biotech services stock fits that profile.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Anthem Biosciences Financials: Strong Margins, Lumpy Quarters

The biotech services stock runs some of the highest margins among Indian pharma services companies, but revenue swings from quarter to quarter because deliveries follow customer schedules. The table below shows the last five quarters on a consolidated basis.

Quarter	Revenue (Rs Cr)	Operating Profit (Rs Cr)	OPM (%)	Net Profit (Rs Cr)
Jun 2025	540	191	35%	136
Sep 2025	550	218	40%	173
Dec 2025	423	157	37%	93
Mar 2026	611	267	44%	190
Jun 2026	418	151	36%	120

The June 2026 quarter, reported on 22 July 2026, was the weak spot for the biotech services stock. Revenue fell about 23% year on year to Rs 418 crore and net profit declined about 12% to approximately Rs 120 crore. Management blamed shifts in the timing of customer shipments rather than lost business.

The Anthem Biosciences share price fell about 3% to Rs 767 on the result day. The fact that the share later climbed past Rs 940 shows investors treated the miss as a timing issue. Even in the weak quarter, company-reported EBITDA margin held at 39.6%.

On an annual basis, operating revenue grew from Rs 1,057 crore in FY23 to Rs 2,124 crore in FY26, while net profit rose from Rs 385 crore to Rs 592 crore. The board recommended a final dividend of Rs 2 per share for FY26.

Who Owns This Biotech Services Stock?

Promoters still own a large majority, but institutions have been steadily raising their stake in this biotech services stock. The shift is clear in the shareholding trend below.

Category	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	74.69%	74.69%	74.67%	71.42%
FIIs	1.66%	1.37%	1.28%	2.57%
DIIs	7.21%	7.60%	11.55%	13.48%
Public	16.42%	16.34%	12.48%	12.52%

DII holding nearly doubled in nine months, and FII holding doubled in the June quarter after the block deal. Public holding shrank from about 16% to 12.5%, which means a smaller free float for retail traders and potentially sharper price swings in the biotech services stock.

Is This Biotech Services Stock Expensive After the Rally?

Yes, by most measures this biotech services stock is richly valued. At Rs 942.30, the Anthem Biosciences share trades at roughly 85 to 92 times trailing earnings, depending on the profit base used, and about 17 times book value. That premium prices in years of strong growth.

Quality metrics for the biotech services stock are solid. Return on equity is around 22% to 24%, return on capital employed is close to 30%, and debt to equity is near zero. The question for investors is whether earnings can grow fast enough to justify the multiple.

Key Risks for This Biotech Services Stock

The biotech services stock carries real risks that the recent rally may be underplaying. Investors should weigh these before tracking the Anthem Biosciences share price further.

Lumpy Revenue and Customer Concentration

For this biotech services stock, CRDMO revenue depends on a limited number of large projects. A single delayed shipment can swing a quarter, as the June 2026 result showed. The loss or delay of one big molecule could hurt growth for several quarters.

High Valuation Leaves Little Room for Error

At a multiple near 90 times earnings, any earnings miss by the biotech services stock can trigger a sharp fall. The share already dropped after the Q1 FY27 result, and a repeat in the second half would likely test investor patience.

Regulatory and Pipeline Timing

The biotech services stock also faces pipeline timing risk. Management flagged delays in regulatory approvals for products such as semaglutide API and uncertainty over the timing of GLP-1 commercialisation. Commercial launches of client drugs are outside the company's control.

Execution on Unit 4 and Promoter Supply

The Rs 1,200 crore expansion must be delivered on time and filled with orders. Further promoter stake sales cannot be ruled out, and new supply could cap near-term gains in the biotech services stock.

Download the Univest iOS App or Univest Android App to track the Anthem Biosciences share price live

Anthem Biosciences Share: Analyst View

Analyst opinion on the biotech services stock is positive on the business but more cautious on price after the rally. Most covering analysts rate the share a buy, citing its integrated platform, high margins and net cash, while flagging valuation.

Anthem Biosciences Share Price Target

In November 2025, a foreign brokerage initiated coverage with a buy rating and an Anthem Biosciences share price target of Rs 740, based on 50 times estimated December 2027 earnings. The share has already moved well above that level, so that Anthem Biosciences share price target now looks dated.

The average analyst Anthem Biosciences share price target is now around Rs 923, with the highest estimate near Rs 1,102 and the lowest around Rs 838. With the Anthem Biosciences share price at Rs 942.30, the stock trades slightly above the average target, which suggests much of the near-term upside is priced in.

Key levels to watch on the biotech services stock are the 52-week high of Rs 977.55 on the upside and the June block deal price of around Rs 745 as a reference zone on the downside.

Conclusion

This biotech services stock has gained 43% in six months on the back of a record Q4 FY26, a successful institutional block deal, a large net cash pile and a clear capacity roadmap. The Anthem Biosciences share price now sits close to its 52-week high after recovering from a soft June quarter.

The business quality behind this biotech services stock is high, but so is the valuation. Revenue is lumpy and the second half of FY27 must deliver the promised pickup. Investors tracking this biotech services stock should watch Q2 FY27 numbers, Unit 4 progress and any further promoter selling before taking a position.

Frequently Asked Questions

Which biotech services stock rose 43% in 6 months?

Ans. Anthem Biosciences Ltd (NSE: ANTHEM) delivered a 6-month return of 43.28% as of 10 September 2026, ranking 35th in a screen of 101 NSE stocks. The share closed at Rs 942.30 that day.

Why did the Anthem Biosciences share price rise?

Ans. The share rose after a record Q4 FY26 in which net profit jumped about 130% to around Rs 190 crore. A Rs 1,275 crore block deal picked up by institutions, net cash of about Rs 1,720 crore and guidance that destocking is over also supported the rally.

What was the Anthem Biosciences IPO price?

Ans. The IPO was priced at Rs 570 per share and the stock listed on the NSE at Rs 723.05 in July 2025, a premium of about 27%. At Rs 942.30, the share trades roughly 65% above the issue price.

What is the Anthem Biosciences share price target?

Ans. A foreign brokerage set a target of Rs 740 in November 2025, which the stock has already crossed. The average analyst target is now around Rs 923, slightly below the current price.

How did Anthem Biosciences perform in Q1 FY27?

Ans. Revenue fell about 23% year on year to Rs 418 crore and net profit declined about 12% to approximately Rs 120 crore. Management attributed the dip to timing shifts in customer deliveries and expects a stronger second half.

Is Anthem Biosciences debt free?

Ans. This biotech services stock is effectively debt free, with borrowings of only around Rs 54 crore in March 2026. It held net cash of approximately Rs 1,720 crore as of 30 June 2026.

What is the 52-week high and low of Anthem Biosciences?

Ans. The 52-week high is Rs 977.55 and the 52-week low is Rs 579.15. The share closed at Rs 942.30 on 10 September 2026, about 4% below its high.

What are the main risks for Anthem Biosciences?

Ans. Key risks for this biotech services stock include lumpy revenue from a limited number of large projects, a valuation near 90 times earnings, regulatory delays for client products and execution on the Rs 1,200 crore Unit 4 expansion.